Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

Summary by Hastings Tribune
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan 20, 2026-

1 Articles

Hastings TribuneHastings Tribune
Center

Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan 20, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Tuesday, January 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alameda icon

Alameda

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal